This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ballantyne, C. M. Articles by Marian, A. J. Search for Related Content PubMed PubMed Citation Articles by Ballantyne, C. M. Articles by Marian, A. J.

Apolipoprotein E genotypes and response of plasma lipids and progression–regression of coronary atherosclerosis to lipid-lowering drug therapy

Christie M. Ballantyne, MD, FACC^*, J. Alan Herd, MD^*, Evan A. Stein, MD, PhD, Laura L. Ferlic, MS^*, J. Kay Dunn, PhD^*, Antonio M. Gotto, Jr., MD, DPhil, FACC and Ali J. Marian, MD, FACC^*

^* Department of Medicine, Baylor College of Medicine, Houston, Texas, USA
Medical Research Laboratories, Highland Heights, Kentucky, USA
Department of Medicine, Weill Medical College of Cornell University, New York, New York, USA

View larger version (15K): [in a new window]   Figure 1 Effect of apo E genotype on lipids (mean percent change ± SD) in response to fluvastatin treatment. At 12-week follow-up, the subjects receiving fluvastatin in the 3/4 and 4/4 genotype group had significantly smaller reductions in total cholesterol (TC) (p = 0.01) and LDL cholesterol (p = 0.03) than did subjects in the 3/3 genotype group. For HDL cholesterol, the subjects receiving fluvastatin in the 2/3 genotype group had significantly greater increases than did the subjects in either the 3/3 genotype group (p = 0.002) or the 3/4 and 4/4 genotype group (p = 0.02). There was no significant interaction between treatment and genotype for changes in triglyceride (TG) levels. Solid bar = 2/3 genotype; open bar = 3/3 genotype; shaded bar = 3/4 and 4/4 genotypes.